Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Non-destructive testing and assembly control

Assess complete assembly.

The future of healthcare in focus: ”Together, things happen”

In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowl...

MSD i storaffär – köper rättigheter till hjärt-kärlkandidat

Merck & Co, känt som MSD utanför USA och Kanada, har ingått ett exklusivt licensavtal med kinesiska Hengrui Pharma. Avtalet rör rättigheterna till läkemedelskan...

Microscopy in Urinalysis: Observe Urine, Detect Abnormalities

Webinar on 18th March 2025, 10 AM - 11 AM CET.

New moves around Nykode's management – withdrawal of resignations

Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.

After the threat of tariffs – Novartis invests 230 billion in the USA

Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...

Scale Up Your Image Analysis

ZEISS arivis Hub for accelerated analysis and faster results.

Cost-efficient development of laboratory devices

8 ways to optimise development costs and speed up processes

Webinar: Automate your processes

Free ZEISS webinar on January 30th, 2025.

Quality solutions for medical device R&D applications

From R&D to the quality assurance of series production in medical device manufacturing.

AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence

AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.

Alzecure får EU-miljoner till alzheimerstudie

Alzecure Pharma beviljas 2,5 miljoner euro, motsvarande 28 miljoner kronor, i EU-anslag för sitt projekt inom Alzheimers sjukdom.

New Horizons in Biologics & Bioprocessing: Copenhagen 2026

High-performance Slide Scanner for Fluorescence, Brightfield and Polarization

ZEISS Axioscan 7.

Bioscience – Groundbreaking Research & Diagnostics: Gothenburg 2026

Assignment: Facilitate the retention of foreign researchers

A newly appointed public inquiry is to develop measures to make attracting and retaining foreign doctoral students and researchers in Sweden easier.

In search of Marcel Proust's lost health

A great writer, but also a weak person and a hypochondriac. That has been the usual image of Marcel Proust. But the pediatrician and literary scholar Carl Lindg...

Fundamental Aspects of Airy Disk Patterns

Knowledge Article from ZEISS.

JMP Statistical Discovery

Are you curious about volume imaging for very large samples?

Exciting ZEISS Webinar!

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

Webinar: Support Trial Patients Transitioning to the Commercial Space

Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.

Bioarctics forskningschef Johanna Fälting tar plats i VR:s ämnesråd

Bioarctics forskningschef Johanna Fälting och läkaren Markus Lingman har utsetts till nya ledamöter i Vetenskapsrådets ämnesråd för medicin och hälsa.